HIV Drug Settlement Reached to Resolve Class Action Over Truvada, Stribild, Other Antiretrovirals
Bristol-Myers Squibb has agreed to pay $10 million to resolve its part in the class action lawsuit over HIV drugs with allegedly inflated prices.
Bristol-Myers Squibb has agreed to pay $10 million to resolve its part in the class action lawsuit over HIV drugs with allegedly inflated prices.
This and similar lawsuits claim Gilead sat on a safer formulation of its HIV drug for years in order to maximize its profits from the older, more toxic version.
Lawsuit indicates Gilead sat on safer drug formulations until it completely cashed in on the older, more dangerous TDF-based HIV drugs.